Multi-Antigen T Cell Therapy Shows 84.6% Disease Control Rate in Pancreatic Cancer Phase 1/2 Trial
核心洞察
Baylor College of Medicine researchers published results in Nature Medicine showing Multi-Antigen Targeted T cells (搜索) achieved an 84.6% disease control rate when combined with frontline chemotherapy in pancreatic cancer (搜索) patients.
The Phase 1/2 clinical study demonstrated a median overall survival of 14.1 months and median duration of response of 7.5 months for patients achieving partial or complete responses.
Infused T cells remained detectable in patients 12 months post-treatment and were found at higher frequencies in patients who responded to the investigational therapy.
Researchers at Baylor College of Medicine have published groundbreaking results in Nature Medicine demonstrating the clinical potential of Multi-Antigen Targeted T cells (搜索) in treating pancreatic cancer (搜索), with the therapy achieving an 84.6% disease control rate when combined with standard chemotherapy. The Phase 1/2 clinical study represents a significant advancement in addressing one of oncology's most challenging malignancies.
Clinical Efficacy and Safety Profile
The Phase 1/2 clinical study conducted at Baylor College of Medicine evaluated Multi-Antigen Targeted T cells (搜索) in combination with frontline chemotherapy (Arm A) in patients with pancreatic cancer (搜索). The trial demonstrated encouraging objective clinical responses, with a disease control rate of 84.6%. For patients achieving a partial or complete response, the median duration of response was 7.5 months, ranging from 3.5 to 16.6 months.
The study showed a median overall survival rate of 14.1 months, suggesting a clinical benefit of combining Multi-Antigen Targeted T cells (搜索) with standard chemotherapy. Clinical results demonstrated a favorable safety profile and potential synergistic effect when combining the T cell therapy with chemotherapy without affecting the toxicity profile.
Mechanism of Action and Persistence
The research team highlighted a correlation between clinical effect and the expansion and persistence of infused Multi-Antigen Targeted T cells (搜索). Data showed that infused T cells were still present in patients 12 months post-treatment and were found at higher frequencies in patients who responded to the investigational product.
Chemotherapy was previously shown to break down the tumor's supporting stromal cells, which act as a protective barrier, facilitating T cell infiltration into the tumor and boosting anti-tumor response, according to research published in Frontiers in Oncology in 2023.
Technology Platform and Development
The multi-antigen recognizing (MAR) T cell platform represents a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient's blood capable of recognizing a broad range of tumor antigens. Unlike other T cell therapies, MAR-T cells (搜索) allow the recognition of hundreds of different epitopes within up to six tumor-specific antigens, thereby reducing the possibility of tumor escape.
Since MAR-T cells (搜索) are not genetically engineered, Marker Therapeutics believes its product candidates will be easier and less expensive to manufacture, with an improved safety profile compared to current engineered T cell approaches.
Commercial Development and Future Plans
"We congratulate the research team at Baylor College of Medicine on this outstanding work and encouraging results in patients with pancreatic cancer (搜索)," said Juan Vera, MD, President and CEO of Marker Therapeutics. "The data highlights the excellent safety profile of Multi-Antigen Targeted T cells (搜索) and demonstrates that they can be used in combination with frontline chemotherapy."
Marker Therapeutics has advanced the technology, referring to it as MAR-T cells (搜索), and plans to build on the Baylor study results by increasing the number of target antigens, using higher cell doses, and adding lymphodepletion to support the expansion of infused MAR-T cells. The company anticipates clinical initiation of its pancreatic cancer (搜索) program in the first half of 2026.
Supporting Clinical Data
The company recently reported promising safety and efficacy results from its Phase 1 study investigating MAR-T cell product MT-601 in lymphoma (搜索) (APOLLO study). This study resulted in a 66% objective response rate in patients with non-Hodgkin lymphoma (搜索), with 50% achieving complete response. Improvements from this clinical study will be incorporated into the pancreatic cancer (搜索) program.
MT-601 utilizes a non-genetically modified approach that specifically targets six different tumor antigens upregulated in tumor cells: Survivin (搜索), PRAME (搜索), WT-1, NY-ESO-1 (搜索), SSX-2 (搜索), and MAGEA-4 (搜索).
Funding and Development Support
Marker Therapeutics has secured non-dilutive funding from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program and the Cancer Prevention and Research Institute of Texas (CPRIT) to support the pancreatic cancer (搜索) program. The company anticipates that using these allocated non-dilutive funds will allow it to proceed with the pancreatic program without affecting its financial runway or efforts to advance MT-601 in lymphoma (搜索) patients in the ongoing Phase 1 APOLLO study.